“Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s612, https://doi.org/10.25251/m9gw3y80.